Melanoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | BRAF p.V600E | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| FDA (1) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| EMA (2) FDA (2) HSE (1) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| EMA (2) FDA (2) HSE (1) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib | |
| EMA (1) FDA (1) HSE (1) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (1) HSE (1) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (1) HSE (1) | BRAF p.V600E | Melanoma | Dabrafenib | |
| EMA (4) FDA (4) HSE (2) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| EMA (4) FDA (4) HSE (2) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600E | Melanoma | Trametinib | |
| EMA (1) FDA (1) | BRAF p.V600K | Melanoma | Trametinib | |
| EMA (1) FDA (1) HSE (1) | BRAF p.V600E | Melanoma | Vemurafenib | |
| EMA (1) | PD-L1 < 1% | Melanoma | Nivolumab, Relatlimab | |
| EMA (1) HSE (1) | BRAF p.V600K | Melanoma | Dabrafenib | |
| EMA (1) HSE (1) | BRAF p.V600K | Melanoma | Vemurafenib |